Post-Ibrutinib Colitis and Intestinal Microbiota
NCT03569137 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2018-06-26
Summary
Identify gut microbiome biomarkers associated with colitis in patients treated with targeted therapy in hematology
Conditions
- Gastrointestinal Microbiome
Sponsors & Collaborators
-
Vendee Departmental hospital center
collaborator UNKNOWN -
Nantes University Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-01
- Primary Completion
- 2019-08-01
- Completion
- 2020-08-01
Countries
- France
Study Locations
More Related Trials
-
Pathophysiological Effects of Persistently Colonized Microbiome on Irritable Bowel Syndrome
NCT06013410 ·Status: RECRUITING ·Phase: NA
-
New Microbiota-endocrine Axis in Fructose Malabsorption-caused Visceral Hypersensitivity in Irritable Bowel Syndrome.
NCT07337707 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Stability of the Microbiome in IBD and IBS
NCT03395548 ·Status: COMPLETED ·Phase: NA
-
Evolution of Oropharyngeal and Rectal Microbiota After Severe Traumatic Brain Injury
NCT03965611 ·Status: ACTIVE_NOT_RECRUITING
-
Gut Microbiome in Inflammatory Bowel Disease
NCT03589183 ·Status: RECRUITING
-
Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome With Constipation
NCT05803993 ·Status: RECRUITING ·Phase: NA
-
Study on the Molecular Mechanism of Diarrhea-predominant Irritable Bowel Syndrome With Anxiety and Depression Based on Multi-omics Correlation Analysis
NCT05311293 ·Status: UNKNOWN
-
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
NCT00394173 ·Status: COMPLETED ·Phase: PHASE2
-
Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients
NCT02550704 ·Status: COMPLETED ·Phase: NA
-
Microbiota Profiling in IBS
NCT03720314 ·Status: COMPLETED
-
Gastrointestinal Symptoms in Healthy Subjects and Patients With Irritable Bowel Syndrome
NCT01457378 ·Status: COMPLETED
-
Screening of Lactose Intolerance Among IBS Patients Diarrhea Dominant
NCT06931379 ·Status: NOT_YET_RECRUITING
-
Drug Repurposing - Statins as Microbiota Modulating Agents in Ulcerative Colitis
NCT04883840 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Detection of Luminal and Mucosa-associated Microbiome in Healthy Controls vs. Local and Systemic Inflammation
NCT03157687 ·Status: COMPLETED
-
Maastricht IBS Cohort
NCT00775060 ·Status: UNKNOWN
-
Prevention of Irinotecan Induced Diarrhea by Probiotics
NCT01410955 ·Status: COMPLETED ·Phase: PHASE3
-
Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome Without Constipation
NCT05803980 ·Status: RECRUITING ·Phase: NA
-
The Stool Microbiome of Treated and Untreated IBS (Irritable Bowel Syndrome) Patients
NCT05972317 ·Status: RECRUITING ·Phase: NA
-
Effects of Continuous Treatment With Rifaximin and Probiotics on the Gut Microbiota of Patients With IBS-D
NCT04074421 ·Status: UNKNOWN ·Phase: PHASE4
-
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
NCT03557788 ·Status: COMPLETED ·Phase: PHASE4
-
ConfocAl endomicroSCopy bAsed Diet Trial in IBS
NCT05097872 ·Status: RECRUITING ·Phase: NA
-
Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)
NCT00699166 ·Status: COMPLETED ·Phase: PHASE2
-
Cognitive Impairment and Affective Mood Disorders in Patients With IBD
NCT05760729 ·Status: UNKNOWN
-
Functional Gastrointestinal Disorders in Pediatric IBD
NCT03565263 ·Status: COMPLETED
-
Screening of Fabry Disease in Patients With GI Symptoms
NCT04184986 ·Status: UNKNOWN